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Introduction 
This is the first edition of this document for novel coronavirus, an adaption of WHO Clinical management of severe acute 
respiratory infection when MERS-CoV infection is suspected publication (2019).   
This document is intended for clinicians taking care of hospitalised adult and paediatric patients with severe acute respiratory 
infection (SARI) when 2019-nCoV infection is suspected. It is not meant to replace clinical judgment or specialist consultation 
but rather to strengthen clinical management of these patients and provide to up-to-date guidance.  Best practices for SARI 
including IPC and optimized supportive care for severely ill patients are essential. 
This document is organized into the following sections:  
1. Triage: recognize and sort patients with SARI 
2. Immediate implementation of appropriate infection prevention and control (IPC) measures 
3. Early supportive therapy and monitoring 
4. Collection of specimens for laboratory diagnosis 
5. Management of hypoxemic respiratory failure and acute respiratory distress syndrome (ARDS)  
6. Management of septic shock 
7. Prevention of complications 
8. Specific anti-nCoV treatments  
9. Special considerations for pregnant patients 
 
These symbols are used to flag interventions:  
 Do: the intervention is beneficial (strong recommendation) OR the intervention is a best practice statement 
 Don’t: the intervention is known to be harmful. 
 Consider: the intervention may be beneficial in selected patients (conditional recommendation) OR be careful when 
considering this intervention. 
This document aims to provide clinicians with updated interim guidance on timely, effective, and safe supportive management of 
patients with 2019-nCoV and SARI, particularly those with critical illness.  
The recommendations in this document are derived from WHO publications.1-4 Where WHO guidance is not available, we refer to 
evidence-based guidelines.  Members of a WHO global network of clinicians, and clinicians who have treated SARS, MERS or 
severe influenza patients have reviewed the recommendations (see Acknowledgements). For queries, please email outbreak@who.int 
with ‘2019-nCoV clinical question’ in the subject line. 
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1. Triage: early recognition of patients with SARI associated with 2019-nCoV infection 
 Triage: recognize and sort all patients with SARI at first point of contact with health care system (such as the emergency 
department).  Consider 2019-nCOV as a possible etiology of SARI under certain conditions (see Table 1). Triage patients and start 
emergency treatments based based on disease severity. 
 
Remarks: 2019-nCoV infection may present with mild, moderate, or severe illness; the latter includes severe pneumonia, ARDS, 
sepsis and septic shock.  Early recognition of suspected patients allows for timely initiation of IPC (see Table 2).  Early 
identification of those with severe manifestations (see Table 2) allows for immediate optimized supportive care treatments 
and safe, rapid admission (or referral) to intensive care unit according to institutional or national protocols.  For those with 
mild illness, hospitalization may not be required unless there is concern for rapid deterioration. All patients discharged home 
should be instructed to return to hospital if they develop any worsening of illness. 
 
 
 
Table 1. Definitions of patients with SARI, suspected of 2019-nCoV infection*  
SARI An ARI with history of fever or measured temperature ≥38 C° and cough; onset within the last ~10 days; and requiring 
hospitalization.5 However, the absence of fever does NOT exclude viral infection.6  
Surveillance 
case definitions 
for 2019-nCoV*  
A. Patients with severe acute respiratory infection (fever, cough, and requiring admission to hospital), AND with no other 
etiology that fully explains the clinical presentation1 AND at least one of the following: 
• a history of travel to or residence in the city of Wuhan, Hubei Province, China in the 14 days prior to symptom onset, 
or 
• patient is a health care worker who has been working in an environment where severe acute respiratory infections of 
unknown etiology are being cared for. 
 
B. Patients with any acute respiratory illness AND at least one of the following: 
• close contact2 with a confirmed or probable case of 2019-nCoV in the 14 days prior to illness onset, or 
• visiting or working in a live animal market in Wuhan, Hubei Province, China in the 14 days prior to symptom onset, 
or 
• worked or attended a health care facility in the 14 days prior to onset of symptoms where patients with hospital-
associated 2019-nCov infections have been reported. 
*see https://www.who.int/health-topics/coronavirus for latest case definitions 
1 clinicians should also be alert to the possibility of atypical presentations in patients who are immunocompromised; 
2: Close contact’ is defined as: 
- Health care associated exposure, including providing direct care for nCoV patients, working with health care workers infected with novel coronavirus, 
visiting patients or staying in the same close environment as a nCoV patient. 
- Working together in close proximity or sharing the same classroom environment with a nCoV patient 
- Traveling together with a nCoV patient in any kind of conveyance 
- Living in the same household as a nCoV patient 
The epidemiological link may have occurred within a 14‐day period from onset of illness in the case under consideration.  
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Table 2. Clinical syndromes associated with 2019-nCoV infection 
Uncomplicated 
illness 
Patients with uncomplicated upper respiratory tract viral infection, may have non-specific symptoms such as fever, cough, sore 
throat, nasal congestion, malaise, headache, muscle pain or malaise.  The elderly and immunosuppressed may present with 
atypical symptoms.  These patients do not have any signs of dehydration, sepsis or shortness of breath.  
Mild pneumonia  Patient with pneumonia and no signs of severe pneumonia. 
Child with non-severe pneumonia has cough or difficulty breathing + fast breathing: fast breathing (in breaths/min): <2 months, 
≥60; 2–11 months, ≥50; 1–5 years, ≥40 and no signs of severe pneumonia. 
Severe 
pneumonia 
Adolescent or adult: fever or suspected respiratory infection, plus one of respiratory rate >30 breaths/min, severe respiratory 
distress, or SpO2 <90% on room air (adapted from [1]).  
Child with cough or difficulty in breathing, plus at least one of the following: central cyanosis or SpO2 <90%; severe respiratory 
distress (e.g. grunting, very severe chest indrawing); signs of pneumonia with a general danger sign: inability to breastfeed or 
drink, lethargy or unconsciousness, or convulsions. Other signs of pneumonia may be present: chest indrawing, fast breathing (in 
breaths/min): <2 months, ≥60; 2–11 months, ≥50; 1–5 years, ≥40.2 The diagnosis is clinical; chest imaging can exclude 
complications.  
Acute 
Respiratory 
Distress 
Syndrome7-9 
 
Onset: new or worsening respiratory symptoms within one week of known clinical insult. 
Chest imaging (radiograph, CT scan, or lung ultrasound): bilateral opacities, not fully explained by effusions, lobar or lung 
collapse, or nodules. 
Origin of oedema: respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (e.g. 
echocardiography) to exclude hydrostatic cause of oedema if no risk factor present. 
Oxygenation (adults):  
• Mild ARDS: 200 mmHg < PaO2/FiO2 ≤ 300 mmHg (with PEEP or CPAP ≥5 cmH2O,7 or non-ventilated8) 
• Moderate ARDS: 100 mmHg < PaO2/FiO2 ≤200 mmHg with PEEP ≥5 cmH2O,7 or non-ventilated8) 
• Severe ARDS: PaO2/FiO2 ≤ 100 mmHg with PEEP ≥5 cmH2O,7 or non-ventilated8) 
• When PaO2 is not available, SpO2/FiO2 ≤315 suggests ARDS (including in non-ventilated patients) 
Oxygenation (children; note OI = Oxygenation Index and OSI = Oxygenation Index using SpO2):  
• Bilevel NIV or CPAP ≥5 cmH2O via full face mask: PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤264 
• Mild ARDS (invasively ventilated): 4 ≤ OI < 8 or 5 ≤ OSI < 7.5 
• Moderate ARDS (invasively ventilated): 8 ≤ OI < 16 or 7.5 ≤ OSI < 12.3 
• Severe ARDS (invasively ventilated): OI ≥ 16 or OSI ≥ 12.3 
Sepsis10,11 
 
Adults: life-threatening organ dysfunction caused by a dysregulated host response to suspected or proven infection, with organ 
dysfunction*.  Signs of organ dysfunction include: altered mental status, difficult or fast breathing, low oxygen saturation, reduced 
urine output, fast heart rate, weak pulse, cold extremities or low blood pressure, skin mottling, or laboratory evidence of 
coagulopathy, thrombocytopenia, acidosis, high lactate or hyperbilirubinemia.  
Children: suspected or proven infection and ≥2 SIRS criteria, of which one must be abnormal temperature or white blood cell 
count. 
Septic 
shock10,12 
Adults: persisting hypotension despite volume resuscitation, requiring vasopressors to maintain MAP ≥65 mmHg and serum 
lactate level >2 mmol/L.   
Children (based on [12]): any hypotension (SBP <5th centile or >2 SD below normal for age) or 2-3 of the following: altered mental 
state; tachycardia or bradycardia (HR <90 bpm or >160 bpm in infants and HR <70 bpm or >150 bpm in children); prolonged 
capillary refill (>2 sec) or warm vasodilation with bounding pulses; tachypnea; mottled skin or petechial or purpuric rash; increased 
lactate; oliguria; hyperthermia or hypothermia. 
Abbreviations: ARI, acute respiratory infection; BP, blood pressure; bpm, beats/minute; CPAP, continuous positive airway pressure; FiO2, fraction of inspired oxygen; MAP, mean 
arterial pressure; NIV, noninvasive ventilation; OI, Oxygenation Index; OSI, Oxygenation Index using SpO2; PaO2, partial pressure of oxygen; PEEP, positive end-expiratory 
pressure; SBP, systolic blood pressure; SD, standard deviation; SIRS, systemic inflammatory response syndrome; SpO2, oxygen saturation. *If altitude is higher than 1000m, then 
correction factor should be calculated as follows: PaO2/FiO2 x Barometric pressure/760.  
* The SOFA score ranges from 0 to 24 and includes points related to 6 organ systems: respiratory (hypoxemia defined by low PaO2/FiO2), coagulation (low platelets), liver (high 
bilirubin), cardiovascular (hypotension), central nervous system (low level of consciousness defined by Glasgow Coma Scale), and renal (low urine output or high creatinine).  
Sepsis is defined by an increase in the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score13 of ≥2 points. Assume the baseline score is zero if data are not 
available 
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2. Immediate implementation of appropriate IPC measures 
IPC is a critical and integral part of clinical management of patients and should be initiated at the point of entry of the patient to 
hospital (typically the Emergency Department). Standard precautions should always be routinely applied in all areas of health care 
facilities. Standard precautions include hand hygiene; use of PPE to avoid direct contact with patients’ blood, body fluids, 
secretions (including respiratory secretions) and non-intact skin. Standard precautions also include prevention of needle-stick or 
sharps injury; safe waste management; cleaning and disinfection of equipment; and cleaning of the environment. 
Table 2. How to implement infection prevention and control measures for patients with suspected or confirmed 2019-nCoV infection 
14,15 
At triage Give suspect patient a medical mask and direct patient to separate area, an isolation room if available.  Keep at least 1meter 
distance between suspected patients and other patients.  Instruct all patients to cover nose and mouth during coughing or 
sneezing with tissue or flexed elbow for others.  Perform hand hygiene after contact with respiratory secretions 
Apply droplet precautions Droplet precautions prevent large droplet transmission of respiratory viruses. Use a medical mask if working within 1-2 metre s 
of the patient. Place patients in single rooms, or group together those with the same etiological diagnosis. If an etiological 
diagnosis is not possible, group patients with similar clinical diagnosis and based on epidemiological risk factors, with a spatial 
separation. When providing care in close contact with a patient with respiratory symptoms (e.g. coughing or sneezing), use eye 
protection (face-mask or goggles), because sprays of secretions may occur. Limit patient movement within the institution and 
ensure that patients wear medical masks when outside their rooms.  
Apply contact precautions Droplet and contact precautions prevent direct or indirect transmission from contact with contaminated surfaces or equipment 
(i.e. contact with contaminated oxygen tubing/interfaces). Use PPE (medical mask, eye protection, gloves and gown) when 
entering room and remove PPE when leaving. If possible, use either disposable or dedicated equipment (e.g. stethoscopes, 
blood pressure cuffs and thermometers). If equipment needs to be shared among patients, clean and disinfect between each 
patient use. Ensure that health care workers refrain from touching their eyes, nose, and mouth with potentially contaminated 
gloved or ungloved hands. Avoid contaminating environmental surfaces that are not directly related to patient care (e.g. door 
handles and light switches). Ensure adequate room ventilation. Avoid movement of patients or transport. Perform hand 
hygiene.  
Apply airborne 
precautions when 
performing an aerosol 
generating procedure 
Ensure that healthcare workers performing aerosol-generating procedures (i.e. open suctioning of respiratory tract, 
intubation, bronchoscopy, cardiopulmonary resuscitation) use PPE, including gloves, long-sleeved gowns, eye protection, 
and fit-tested particulate respirators (N95 or equivalent, or higher level of protection). (The scheduled fit test should not be 
confused with user seal check before each use.) Whenever possible, use adequately ventilated single rooms when performing 
aerosol-generating procedures, meaning negative pressure rooms with minimum of 12 air changes per hour or at least 160 
litres/second/patient in facilities with natural ventilation. Avoid the presence of unnecessary individuals in the room. Care for the 
patient in the same type of room after mechanical ventilation commences.  
Abbreviations: ARI, acute respiratory infection; PPE, personal protective equipment  
 
3. Early supportive therapy and monitoring 
  Give supplemental oxygen therapy immediately to patients with SARI and respiratory distress, hypoxaemia, or shock. 
Remarks: Initiate oxygen therapy at 5 L/min and titrate flow rates to reach target SpO2 ≥90% in non-pregnant adults and SpO2 
≥92-95 % in pregnant patients.1,2 Children with emergency signs (obstructed or absent breathing, severe respiratory distress, 
central cyanosis, shock, coma or convulsions) should receive oxygen therapy during resuscitation to target SpO2 ≥94%; otherwise, 
the target SpO2 is ≥90%.4 All areas where patients with SARI are cared for should be equipped with pulse oximeters, functioning 
oxygen systems and disposable, single-use, oxygen-delivering interfaces (nasal cannula, simple face mask, and mask with 
reservoir bag). Use contact precautions when handling contaminated oxygen interfaces of patients with nCoV infection. 
 Use conservative fluid management in patients with SARI when there is no evidence of shock. 
Remarks: Patients with SARI should be treated cautiously with intravenous fluids, because aggressive fluid resuscitation may 
worsen oxygenation, especially in settings where there is limited availability of mechanical ventilation.16  
 Give empiric antimicrobials to treat all likely pathogens causing SARI. Give antimicrobials within one hour of initial patient 
assessment for patients with sepsis. 
Remarks: Although the patient may be suspected to have nCoV, administer appropriate empiric antimicrobials within ONE hour 
of identification of sepsis.17 Empiric antibiotic treatment should be based on the clinical diagnosis (community-acquired 
pneumonia, health care-associated pneumonia [if infection was acquired in healthcare setting], or sepsis), local epidemiology and 
susceptibility data, and treatment guidelines. Empiric therapy includes a neuraminidase inhibitor for treatment of influenza when 
there is local circulation or other risk factors, including travel history or exposure to animal influenza viruses.18 Empiric therapy 
should be de-escalated on the basis of microbiology results and clinical judgment.  
 Do not routinely give systemic corticosteroids for treatment of viral pneumonia or ARDS outside of clinical trials unless they are 
indicated for another reason.  
Remarks: A systematic review of observational studies of corticosteroids administered to patients with SARS reported no survival 
benefit and possible harms (avascular necrosis, psychosis, diabetes, and delayed viral clearance).19 A systematic review of 
observational studies in influenza found a higher risk of mortality and secondary infections with corticosteroids; the evidence was 
judged as very low to low quality due to confounding by indication.20 A subsequent study that addressed this limitation by 
adjusting for time-varying confounders found no effect on mortality.21 Finally, a recent study of patients receiving corticosteroids 
for MERS used a similar statistical approach and found no effect of corticosteroids on mortality but delayed lower respiratory 
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tract (LRT) clearance of MERS-CoV.22 Given lack of effectiveness and possible harm, routine corticosteroids should be avoided 
unless they are indicated for another reason. See section 6 for the use of corticosteroids in sepsis. 
 Closely monitor patients with SARI for signs of clinical deterioration, such as rapidly progressive respiratory failure and sepsis, 
and apply supportive care interventions immediately. 
Remarks: Application of timely, effective, and safe supportive therapies is the cornerstone of therapy for patients that develop 
severe manifestations of 2019-nCoV. 
 Understand the patient’s co-morbid condition(s) to tailor the management of critical illness and appreciate the prognosis. 
Communicate early with patient and family. 
Remarks: During intensive care management of SARI, determine which chronic therapies should be continued and which 
therapies should be stopped temporarily. Communicate proactively with patients and families and provide support and prognostic 
information. Understand the patient’s values and preferences regarding life-sustaining interventions. 
 
4. Collection of specimens for laboratory diagnosis 
WHO guidance on specimen collection, processing, and laboratory testing, including related biosafety procedures, is available.23 
 
  Collect blood cultures for bacteria that cause pneumonia and sepsis, ideally before antimicrobial therapy. DO NOT delay 
antimicrobial therapy to collect blood cultures. 
 
  Collect specimens from BOTH the upper respiratory tract (URT; nasopharyngeal and oropharyngeal) AND lower respiratory tract 
(LRT; expectorated sputum, endotracheal aspirate, or bronchoalveolar lavage) for 2019-nCoV testing by RT-PCR. Clinicians may 
elect to collect only LRT samples when these are readily available (for example, in mechanically ventilated patients). 
 
  Serology for diagnostic purposes is recommended only when RT-PCR is not available.23 
Remarks: Use appropriate PPE for specimen collection (droplet and contact precautions for URT specimens; airborne precautions 
for LRT specimens). When collecting URT samples, use viral swabs (sterile Dacron or rayon, not cotton) and viral transport 
media. Do not sample the nostrils or tonsils. In a patient with suspected novel coronavirus, especially with pneumonia or severe 
illness, a single URT sample does not exclude the diagnosis, and additional URT and LRT samples are recommended.23 LRT (vs. 
URT) samples are more likely to be positive and for a longer period.23 Clinicians may elect to collect only LRT samples when 
these are readily available (for example, in mechanically ventilated patients).  Sputum induction should be avoided due to 
increased risk of increasing aerosol transmission.  
Remarks:  Dual infections with other respiratory viral infections have been found in SARS and MERS cases. At this stage we 
need detailed microbiologic studies in all suspected cases.  Both URT and LRT specimens can tested for other respiratory viruses, 
such as influenza A and B (including zoonotic influenza A), respiratory syncytial virus, parainfluenza viruses, rhinoviruses, 
adenoviruses, enteroviruses (e.g. EVD68), human metapneumovirus, and endemic human coronaviruses (i.e. HKU1, OC43, 
NL63, and 229E). LRT specimens can also be tested for bacterial pathogens, including Legionella pneumophila.   
  In hospitalized patients with confirmed 2019-nCoV infection, repeat URT and LRT samples should be collected to demonstrate 
viral clearance. The frequency of specimen collection will depend on local circumstances but should be at least every 2 to 4 
days until there are two consecutive negative results (both URT and LRT samples if both are collected) in a clinically recovered 
patient at least 24 hours apart. If local infection control practice requires two negative results before removal of droplet 
precautions, specimens may be collected as often as daily.  
5. Management of hypoxemic respiratory failure and ARDS 
 Recognize severe hypoxemic respiratory failure when a patient with respiratory distress is failing standard oxygen therapy. 
Remarks: Patients may continue to have increased work of breathing or hypoxemia even when oxygen is delivered via a face 
mask with reservoir bag (flow rates of 10-15 L/min, which is typically the minimum flow required to maintain bag inflation; FiO2 
0.60-0.95). Hypoxemic respiratory failure in ARDS commonly results from intrapulmonary ventilation-perfusion mismatch or 
shunt and usually requires mechanical ventilation. 
 High-flow nasal oxygen (HFNO) or non-invasive ventilation (NIV) should only be used in selected patients with hypoxemic 
respiratory failure. The risk of treatment failure is high in patients with MERS treated with NIV, and patients treated with either 
HFNO or NIV should be closely monitored for clinical deterioration. 
Remark 1:  HFNO systems can deliver 60 L/min of gas flow and FiO2 up to 1.0; paediatric circuits generally only handle up to 15 
L/min, and many children will require an adult circuit to deliver adequate flow. Compared to standard oxygen therapy, HFNO 
reduces the need for intubation.24 Patients with hypercapnia (exacerbation of obstructive lung disease, cardiogenic pulmonary 
oedema), hemodynamic instability, multi-organ failure, or abnormal mental status should generally not receive HFNO, although 
emerging data suggest that HFNO may be safe in patients with mild-moderate and non-worsening hypercapnia.25 Patients 
receiving HFNO should be in a monitored setting and cared for by experienced personnel capable of endotracheal intubation in 
case the patient acutely deteriorates or does not improve after a short trial (about 1 hr). Evidence-based guidelines on HFNO do 
not exist, and reports on HFNO in MERS patients are limited.26 
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Remark 2: NIV guidelines make no recommendation on use in hypoxemic respiratory failure (apart from cardiogenic pulmonary 
oedema and post-operative respiratory failure) or pandemic viral illness (referring to studies of SARS and pandemic influenza).27 
Risks include delayed intubation, large tidal volumes, and injurious transpulmonary pressures. Limited data suggest a high failure 
rate when MERS patients receive NIV.28 Patients receiving a trial of NIV should be in a monitored setting and cared for by 
experienced personnel capable of endotracheal intubation in case the patient acutely deteriorates or does not improve after a short 
trial (about 1 hr). Patients with hemodynamic instability, multiorgan failure, or abnormal mental status should not receive NIV. 
 
Remark 3: Recent publications suggest that newer HFNO and NIV systems with good interface fitting do not create widespread 
dispersion of exhaled air and therefore should be associated with low risk of airborne transmission.29-31 
 
 
 Endotracheal intubation should be performed by a trained and experienced provider using airborne precautions. 
Remarks: Patients with ARDS, especially young children or those who are obese or pregnant, may desaturate quickly during 
intubation. Pre-oxygenate with 100% FiO2 for 5 minutes, via a face mask with reservoir bag, bag-valve mask, HFNO, or NIV. 
Rapid sequence intubation is appropriate after an airway assessment that identifies no signs of difficult intubation32.  
The following recommendations in this section pertain to mechanically ventilated patients with ARDS.17,33 These focus on adults; 
consensus-based recommendations for children are available.34 
 Implement mechanical ventilation using lower tidal volumes (4–8 ml/kg predicted body weight, PBW) and lower inspiratory 
pressures (plateau pressure <30 cmH2O). 
Remarks: This is a strong recommendation from a clinical guideline for patients with ARDS,33 and is suggested for patients with 
sepsis-induced respiratory failure who do not meet ARDS criteria.17 The initial tidal volume is 6 ml/kg PBW; tidal volume up to 8 
ml/kg PBW is allowed if undesirable side effects occur (e.g. dyssynchrony, pH <7.15). Hypercapnia is permitted if meeting the 
pH goal of 7.30-7.45. Ventilator protocols are available.35 The use of deep sedation may be required to control respiratory drive 
and achieve tidal volume targets. Although high driving pressure (plateau pressure−PEEP) may more accurately predict increased 
mortality in ARDS compared to high tidal volume or plateau pressure,36 RCTs of ventilation strategies that target driving pressure 
are not currently available.  
 
 In patients with severe ARDS, prone ventilation for >12 hours per day is recommended.  
Remarks: Application of prone ventilation is strongly recommended for adult and paediatric patients with severe ARDS33 but 
requires sufficient human resources and expertise to be performed safely.37,38 
 
 Use a conservative fluid management strategy for ARDS patients without tissue hypoperfusion. 
Remarks: This is a strong guideline recommendation;17 the main effect is to shorten the duration of ventilation. See reference [39] 
for details of a sample protocol. 
 
 In patients with moderate or severe ARDS, higher PEEP instead of lower PEEP is suggested. 
Remarks: PEEP titration requires consideration of benefits (reducing atelectrauma and improving alveolar recruitment) vs. risks 
(end-inspiratory overdistension leading to lung injury and higher pulmonary vascular resistance). Tables are available to guide 
PEEP titration based on the FiO2 required to maintain SpO2.35 A related intervention of recruitment manoeuvres (RMs) is 
delivered as episodic periods of high continuous positive airway pressure [30–40 cm H2O], progressive incremental increases in 
PEEP with constant driving pressure, or high driving pressure; considerations of benefits vs. risks are similar. Higher PEEP and 
RMs were both conditionally recommended in a clinical practice guideline.33 For PEEP, the guideline considered an individual 
patient data meta-analysis40 of 3 RCTs. However, a subsequent RCT of high PEEP and prolonged high-pressure RMs showed 
harm, suggesting that the protocol in this RCT should be avoided.41 Monitoring of patients to identify those who respond to the 
initial application of higher PEEP or a different RM protocol, and stopping these interventions in non-responders, is suggested.42  
 
 In patients with moderate-severe ARDS (PaO2/FiO2 <150), neuromuscular blockade by continuous infusion should not be 
routinely used.  
Remarks: One trial found that this strategy improved survival in patients with severe ARDS (PaO2/FiO2 <150) without causing 
significant weakness,43 but results of a recent larger trial found that use of neuromuscular blockage with high PEEP  strategy was 
not associated with survival when compared to a light sedation strategy without neuromuscular blockade44. Continuous 
neuromuscular blockade may still be considered in patients with ARDS in certain situations: ventilator dyssnchony despite 
sedation, such that tidal volume limitation cannot be reliably achieved; or refractory hypoxemia or hypercapnia. 
 In settings with access to expertise in extracorporeal life support (ECLS), consider referral of patients with refractory hypoxemia 
despite lung protective ventilation. 
Remarks: A recent guideline made no recommendation about ECLS in patients with ARDS.33 Since then, an RCT of ECLS for 
patients with ARDS was stopped early and found no statistically significant difference in the primary outcome of 60-day mortality 
between ECLS and standard medical management (including prone positioning and neuromuscular blockade).45 However, ECLS 
was associated with a reduced risk of the composite outcome of mortality and crossover to ECLS,45 and a post hoc Bayesian 
analysis of this RCT showed that ECLS is very likely to reduce mortality across a range of prior assumptions.46  In patients with 
MERS-CoV infection, ECLS vs. conventional treatment was associated with reduced mortality in a cohort study.47 ECLS should 
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only be offered in expert centres with a sufficient case volume to maintain expertise and that can apply the IPC measures required 
for 2019-nCoV patients.48 
 Avoid disconnecting the patient from the ventilator, which results in loss of PEEP and atelectasis. Use in-line catheters for 
airway suctioning and clamp endotracheal tube when disconnection is required (for example, transfer to a transport ventilator). 
 
6. Management of septic shock 
 Recognize septic shock in adults when infection is suspected or confirmed AND vasopressors are needed to maintain mean 
arterial pressure (MAP) ≥65 mmHg AND lactate is ≥2 mmol/L, in absence of hypovolemia.  
  Recognize septic shock in children with any hypotension (systolic blood pressure [SBP] <5th centile or >2 SD below normal for 
age) or 2-3 of the following: altered mental state; tachycardia or bradycardia (HR <90 bpm or >160 bpm in infants and HR <70 
bpm or >150 bpm in children); prolonged capillary refill (>2 sec) or warm vasodilation with bounding pulses; tachypnea; mottled 
skin or petechial or purpuric rash; increased lactate; oliguria; hyperthermia or hypothermia. 
Remarks: In the absence of a lactate measurement, use MAP and clinical signs of perfusion to define shock. Standard care 
includes early recognition and the following treatments within 1 hour of recognition: antimicrobial therapy and fluid loading and 
vasopressors for hypotension.49 The use of central venous and arterial catheters should be based on resource availability and 
individual patient needs. Detailed guidelines are available for the management of septic shock in adults17 and children.2,3,12 
 In resuscitation from septic shock in adults, give at least 30 ml/kg of isotonic crystalloid in adults in the first 3 hours. In 
resuscitation from septic shock in children in well-resourced settings, give 20 ml/kg as a rapid bolus and up to 40-60 ml/kg in the 
first 1 hr.   
 
    Do not use hypotonic crystalloids, starches, or gelatins for resuscitation. 
 
 Fluid resuscitation may lead to volume overload, including respiratory failure. If there is no response to fluid loading and signs 
of volume overload appear (for example, jugular venous distension, crackles on lung auscultation, pulmonary oedema on 
imaging, or hepatomegaly in children), then reduce or discontinue fluid administration. This step is particularly important where 
mechanical ventilation is not available.  Alternate fluid regimens are suggested when caring for children in resource-limited 
settings50 
Remarks: Crystalloids include normal saline and Ringer’s lactate. Determine need for additional fluid boluses (250-1000 ml in 
adults or 10-20 ml/kg in children) based on clinical response and improvement of perfusion targets. Perfusion targets include 
MAP (>65 mmHg or age-appropriate targets in children), urine output (>0.5 ml/kg/hr in adults, 1 ml/kg/hr in children), and 
improvement of skin mottling, capillary refill, level of consciousness, and lactate. Consider dynamic indices of volume 
responsiveness to guide volume administration beyond initial resuscitation based on local resources and experience.17 These 
indices include passive leg raises, fluid challenges with serial stroke volume measurements, or variations in systolic pressure, 
pulse pressure, inferior vena cava size, or stroke volume in response to changes in intrathoracic pressure during mechanical 
ventilation. 
Starches are associated with an increased risk of death and acute kidney injury vs. crystalloids. The effects of gelatins are less 
clear, but they are more expensive than cyrstalloids.51,52 Hypotonic (vs. isotonic) solutions are less effective at increasing 
intravascular volume. Surviving Sepsis also suggests albumin for resuscitation when patients require substantial amounts of 
crystalloids, but this conditional recommendation is based on low-quality evidence.17 
 Administer vasopressors when shock persists during or after fluid resuscitation. The initial blood pressure target is MAP ≥65 
mmHg in adults and age-appropriate targets in children. 
 
 If central venous catheters are not available, vasopressors can be given through a peripheral IV, but use a large vein and closely 
monitor for signs of extravasation and local tissue necrosis. If extravasation occurs, stop infusion. Vasopressors can also be 
administered through intraosseous needles. 
 
 If signs of poor perfusion and cardiac dysfunction persist despite achieving MAP target with fluids and vasopressors, consider 
an inotrope such as dobutamine. 
Remarks: Vasopressors (i.e. norepinephrine, epinephrine, vasopressin, and dopamine) are most safely given through a central 
venous catheter at a strictly controlled rate, but it is also possible to safely administer them via peripheral vein53 and intraosseous 
needle. Monitor blood pressure frequently and titrate the vasopressor to the minimum dose necessary to maintain perfusion and 
prevent side effects. Norepinephrine is considered first-line in adult patients; epinephrine or vasopressin can be added to achieve 
the MAP target. Because of the risk of tachyarrhythmia, reserve dopamine for selected patients with low risk of tachyarrhythmia 
or those with bradycardia. In children with cold shock (more common), epinephrine is considered first-line, while norepinephrine 
is used in patients with warm shock (less common). 
No RCTs have compared dobutamine to placebo for clinical outcomes.17 
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7. Prevention of complications 
Implement the following interventions (Table 3) to prevent complications associated with critical illness. These interventions are 
based on Surviving Sepsis17 or other guidelines,54-57 and are generally limited to feasible recommendations based on high quality 
evidence. 
Table 3. Prevention of complications  
Anticipated Outcome Interventions 
Reduce days of invasive 
mechanical ventilation 
• Use weaning protocols that include daily assessment for readiness to breathe spontaneously 
• Minimize continuous or intermittent sedation, targeting specific titration endpoints (light sedation unless 
contraindicated) or with daily interruption of continuous sedative infusions 
Reduce incidence of ventilator-
associated pneumonia 
• Oral intubation is preferable to nasal intubation in adolescents and adults 
• Keep patient in semi-recumbent position (head of bed elevation 30-45º) 
• Use a closed suctioning system; periodically drain and discard condensate in tubing 
• Use a new ventilator circuit for each patient; once patient is ventilated, change circuit if it is soiled or damaged but not 
routinely 
• Change heat moisture exchanger when it malfunctions, when soiled, or every 5–7 days 
Reduce incidence of venous 
thromboembolism 
• Use pharmacological prophylaxis (low molecular-weight heparin [preferred if available] or heparin 5000 units 
subcutaneously twice daily) in adolescents and adults without contraindications. For those with contraindications, use 
mechanical prophylaxis (intermittent pneumatic compression devices). 
Reduce incidence of catheter-
related bloodstream infection 
• Use a checklist with completion verified by a real-time observer as reminder of each step needed for sterile insertion 
and as a daily reminder to remove catheter if no longer needed 
Reduce incidence of pressure 
ulcers 
• Turn patient every two hours 
Reduce incidence of stress ulcers 
and gastrointestinal bleeding 
• Give early enteral nutrition (within 24–48 hours of admission) 
• Administer histamine-2 receptor blockers or proton-pump inhibitors in patients with risk factors for GI bleeding. Risk 
factors for gastrointestinal bleeding include mechanical ventilation for ≥48 hours, coagulopathy, renal replacement 
therapy, liver disease, multiple comorbidities, and higher organ failure score 
Reduce incidence of ICU-related 
weakness 
• Actively mobilize the patient early in the course of illness when safe to do so  
 
8. Specific anti-Novel-CoV treatments and clinical research 
 There is no current evidence from RCTs to recommend any specific anti-nCoV treatment for patients with suspected or 
confirmed 2019-nCoV infection. 
 
     Unlicensed treatments should be administered only in the context of ethically-approved clinical trials or the Monitored 
Emergency Use of Unregistered Interventions Framework (MEURI), with strict monitoring.  
https://www.who.int/ethics/publications/infectious-disease-outbreaks/en/  
 
 Clinical characterization protocols are available, at the WHO 2019 nCoV website:   
https://www.who.int/emergencies/diseases/novel-coronavirus-2019.  WHO has established Global 2019-nCoV Clinical Data Platform, for 
member countries to contribute.  Contact EDCARN@who.int for additional questions.  
 
9. Special considerations for pregnant patients 
 Pregnant women with suspected or confirmed 2019-nCoV infection should be treated with supportive therapies as described 
above, taking into account the physiologic adaptations of pregnancy. 
 
 The use of investigational therapeutic agents outside of a research study should be guided by individual risk-benefit analysis 
based on potential benefit for mother and safety to fetus, with consultation from an obstetric specialist and ethics committee. 
 Emergency delivery and pregnancy termination decisions are challenging and based on many factors: gestational age, maternal 
condition, and fetal stability. Consultations with obstetric, neonatal, and intensive care specialists (depending on the condition 
of the mother) are essential.  
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